Cencora, Inc.
COR Healthcare Medical - Distribution NYSE
$339.66
+$2.03 (+0.60%)
Open: $338.11 | High: $341.18 | Low: $336.37 | Prev Close: $337.63
Market Cap: $65.83B
Volume: 1.1M | Avg: 1.6M
Last updated: December 05, 2025 at 10:01 PMInvestment Rating
Neutral
Overall Score: 60/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 415
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 42.72 |
| P/B Ratio | 37.70 |
| P/S Ratio | 0.20 |
| EPS | $7.95 |
| Beta | 0.64 |
| Shares Outstanding | 193.82M |
| 52-Week High | $377.54 |
| 52-Week Low | $223.92 |
| SMA 50 | $338.03 |
| SMA 200 | $298.11 |
| Dividend Yield | 0.66% |
| Annual Dividend | $2.25 |
| Next Earnings | February 04, 2026 01:30 PM ET |
Financial Ratios
| Gross Margin | 3.6% |
| Operating Margin | 0.8% |
| Net Margin | 0.5% |
| ROE | 125.2% |
| ROA | 2.0% |
| Debt/Equity | 4.38 |
| Current Ratio | 0.90 |
| Quick Ratio | 0.55 |
Balance Sheet
| Total Assets | $76.59B |
| Total Liabilities | $75.08B |
| Total Equity | $1.51B |
| Cash | $4.36B |
| Total Debt | $7.66B |
| Net Debt | $3.30B |
Income Statement
| Revenue | $321.33B |
| Gross Profit | $11.48B |
| Operating Income | $2.63B |
| Net Income | $1.57B |
| EBITDA | $3.60B |
| Revenue/Share | $1657.22 |
Cash Flow
| Operating CF | $3.88B |
| CapEx | $667.98M |
| Free Cash Flow | $3.21B |
| Book Value/Share | $9.01 |
| Tangible Book/Share | $-80.99 |
| Equity/Share | $9.01 |
Technical Indicators
| RSI (14) | 29.37 Oversold |
| MACD |
2.72
Signal: 7.73
|
| Volatility | 24.13% |
| Trading Signal | Oversold |
Performance & Returns
| 1 Year | +38.4% |
| Sharpe Ratio | 1.71 Good |
| Volatility (Ann.) | 23.21% Moderate |
| COR (1Y) | +38.4% |
| S&P 500 (1Y) | +11.86% |
| Alpha (Excess Return) | +26.54% |
Sector Comparison (Healthcare)
| Metric | COR | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 42.72 | 31.0 | 80% |
| P/B Ratio | 37.7 | -1.2 | 97% |
| ROE (%) | 125.17% | 7.85% | 97% |
| Net Margin (%) | 0.48% | 10.21% | 10% |
| Stock Score | 415 | 506.0 | 10% |
| 1Y Return (%) | +38.40% | +3.84% | 93% |
Historical Price Analysis (Last 200 Days)
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| COR | $339.66 | $350.53 | $358.52 | $360.25 | $338.03 | $298.11 | 29.37 | 2.72 | 24.13% | 1283055 | Strong Short | Bearish Stack |
Candlestick Patterns
There wasn't any recognizable pattern for the COR stock
News Sentiment
| 📊 Ticker | 📰 Headline | 💭 Sentiment | 📡 Source | 🔗 URL |
|---|---|---|---|---|
| COR | Cencora, Inc. (NYSE:COR) Given Average Rating of “Moderate Buy” by Analysts | Neutral | defenseworld.net | Read More |
| COR | Edgestream Partners L.P. Increases Stock Holdings in Cencora, Inc. $COR | Positive | defenseworld.net | Read More |
| COR | Cencora Enhances Global Pharmaceutical Logistics Services, Cold Chain Capabilities | Neutral | businesswire.com | Read More |
| COR | Cencora, Inc. (COR) Presents at Citi Annual Global Healthcare Conference 2025 Transcript | Neutral | seekingalpha.com | Read More |
| COR | Cencora (COR) Upgraded to Buy: Here's Why | Neutral | zacks.com | Read More |
Company Information
Cencora, Inc. sources and distributes pharmaceutical products. Its U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. The company also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; and pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. The company's International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; and distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers and hospitals primarily in Europe. This segment also provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.
| CEO | Robert Mauch |
| Employees | 42000 |
| Country | US |
| IPO Date | 1995-04-04 |
| Exchange | NYSE |
| Website | https://www.amerisourcebergen.com |
| Sector | Healthcare |
| Industry | Medical - Distribution |
Similar Stocks (Healthcare - Medical - Distribution)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category